Approximately 5% of patients with non-small cell lung cancers (NSCLCs) may respond well to a class of targeted therapies called MET inhibitors due to the presence of a specific genetic mutation, according to a study published in The Oncologist on March 24, 2016.
Embargo Policy: Articles for The Oncologist are embargoed for release until 9 a.m. Eastern U.S. time on the day the article is posted online. This policy applies to members of the media, authors, institutions' public information officers, and the public. Authors may not discuss their work with the media until 1 week before the mailing date or 1 week before online posting of the article, whichever is earlier, and must ensure that the media representatives agree to abide by the embargo policy. The Oncologist may refuse to publish a manuscript, despite acceptance for publication, if it has been prematurely released to the press.
New findings show that 95% of advanced penile cancers harbor one or more genomic mutations associated with targeted therapy, according to a study published in The Oncologist on December 14, 2015. These findings suggest that patients may benefit from a range of current and emerging therapies known to target these mutations.
DURHAM, N.C., Sept. 30, 2015 /PRNewswire-iReach/ -- Expression levels of a key protein involved in tumor cell survival appear to predict response to standard first-line therapy in patients with metastatic clear cell renal cell carcinoma (mCCRCC), according to a new study published in The Oncologist on September 30, 2015. These findings suggest an opportunity to tailor the selection of treatment for patients with mCCRCC.
Afatinib shows promising clinical activity in patients with a difficult-to-treat form of non-small cell lung cancer (NSCLC), according to a new study published in The Oncologist on September 9, 2015. These findings suggest a potential therapeutic role for afatinib in NSCLC patients with few treatment options.
Nearly all advanced esophageal cancers harbor genetic mutations that can be targeted with emerging drug therapies, according to a new study published in The Oncologist on September 2, 2015. These findings suggest a potential role for the use of targeted therapy in addition or as an alternative to conventional treatment in patients with esophageal cancer.
A genetic test for PIK3CA mutations may help to identify patients with HER2-positive breast cancer who are less likely to benefit from combination anti-HER2 therapy, according to a study published in The Oncologist on August 5, 2015. Patients with a low likelihood of response to combination anti-HER2 treatment may be able to focus on more effective treatment options while avoiding the potential side effects of unnecessary dual therapy.
Patients who undergo treatment with anthracycline-based chemotherapy for breast cancer are at risk of developing diastolic dysfunction, according to a new study published in The Oncologist on July 16, 2015. Within 12 months of completing anthracycline treatment, 57% of breast cancer patients had changes on their echocardiograms consistent with diastolic dysfunction.
Classification systems that categorize breast cancers based on estrogen receptor (ER), progesterone receptor (PR), and HER2 expression levels may obscure the heterogeneity of other key tumor features, according to a new study published in The Oncologist on April 23, 2015. Some breast tumors that share a single clinical label, such as triple-negative breast cancer (TNBC), may in fact represent a diverse collection of molecular subtypes.
The majority of gastric cancers harbor genomic alterations (GAs) associated with potential benefit from targeted therapies, according to a new study published in The Oncologist on April 16, 2015. These findings suggest a role for genotype-directed management of locally advanced and metastatic gastric cancer.
In a study published in The Oncologist on March 12, 2015, researchers describe the development of a new model that predicts the risk of unexpected uterine sarcoma in women undergoing minimally invasive procedures for the removal of presumed benign leiomyoma.
A study published in The Oncologist on February 26, 2015, challenges the role of fluorescence in situ hybridization (FISH) testing as the current gold standard for detecting EML4-ALK rearrangements and offers an alternative algorithm for detecting this drug-targetable mutation in patients with advanced lung adenocarcinoma.
A new study published in The Oncologist details a novel approach to identifying patients with stage II colorectal cancer who are most likely to benefit from additional treatment due to a high risk of recurrence following surgery.
A new study published in The Oncologist journal shows that a subset of patients with advanced differentiated thyroid cancer (DTC) and multiple comorbidities in which full-dose sorafenib is considered unsafe can initiate treatment with sorafenib at lower starting doses without adversely affecting efficacy or tolerability compared with full-dose sorafenib. A team of researchers led by Ramona Dadu, MD, at the MD Anderson Cancer Center in Houston, TX, performed a retrospective analysis to evaluate the relationship between sorafenib starting doses and first-line treatment tolerability and efficacy.